72 related articles for article (PubMed ID: 19759112)
21. Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer.
Kitajima K; Suenaga Y; Ueno Y; Maeda T; Ebina Y; Yamada H; Okunaga T; Kubo K; Sofue K; Kanda T; Tamaki Y; Sugimura K
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1268-75. PubMed ID: 25833351
[TBL] [Abstract][Full Text] [Related]
22. Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.
Kitajima K; Ebina Y; Sugimura K
Jpn J Radiol; 2014 Jun; 32(6):313-23. PubMed ID: 24744135
[TBL] [Abstract][Full Text] [Related]
23. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients.
Walentowicz-Sadlecka M; Malkowski B; Walentowicz P; Sadlecki P; Marszalek A; Pietrzak T; Grabiec M
Biomed Res Int; 2014; 2014():234813. PubMed ID: 24719847
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
25. Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.
Tsujikawa T; Yoshida Y; Maeda H; Tsuchida T; Mori T; Kiyono Y; Kimura H; Okazawa H
Br J Radiol; 2012 Jul; 85(1015):1020-4. PubMed ID: 22337690
[TBL] [Abstract][Full Text] [Related]
26. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
27. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
28. Non-
Kalshetty A; Basu S
PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
[TBL] [Abstract][Full Text] [Related]
29. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of 16α-
Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
[TBL] [Abstract][Full Text] [Related]
31. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
32. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
34. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
